The combination of ibrutinib, obinutuzumab, and venetoclax was well tolerated and offered a promising response rate in a phase I/II trial of relapsed and untreated mantle cell lymphoma (MCL) patients. The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is already used to treat relapsed or refractory MCL in Australia and elsewhere. Resistance often develops, however, as ...
Triple combination highly active in mantle cell lymphoma: study
By Dave Levitan
25 Feb 2021